| NCT ID | NCT06619327 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Dementia |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-02-19 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-02-19 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the feasibility and preliminary efficacy of the novel Resilient Together for Dementia (RT-D) intervention for couples following dementia diagnoses. The primary target is emotional distress, and the program aims to prevent chronic distress in at-risk couples.
Eligibility Criteria
Inclusion Criteria: * Recent (\~3 month) chart documented ADRD diagnosis, * ADRD symptom onset after age 65 * Cognitive assessment scores and symptoms consistent with early stage dementia, as determined by the Clinical Dementia Rating Scale scores of .5 or 1.0 * Cognitive awareness of their problems (as determined by the treating neurologist), and ability to understand study and research protocol, as determined by a standardized teach-back method assessment Additional inclusion criteria for dyads are: * English speaking adults (18 years or older) * Dyad lives together * At least one partner endorses clinically significant emotional distress during screening (\>7 on Hospital Anxiety and Depression scale subscales or \<5 on the Geriatric Depression Scale) Exclusion Criteria: * Patient is deemed inappropriate by the neurology team * Either partner has a co-occurring terminal illness * Patient was diagnosed with forms of dementia with clinical profiles that would preclude participation (e.g., Frontotemporal Dementia- behavioral variant), as determined by treatment team.
Contact & Investigator
Sarah Bannon, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT06619327 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06619327 currently recruiting?
Yes, NCT06619327 is actively recruiting participants. Contact the research team at sarah.bannon@mountsinai.org for enrollment information.
Where is the NCT06619327 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06619327 clinical trial?
NCT06619327 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Sarah Bannon, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 24 participants.